

Haematologica
HAEMATOL/2019/245795
Version 3

Fc γ RIIb-BCR co-ligation inhibits BCR signaling in chronic lymphocytic leukemia

Rosa Bosch, Alba Mora, Carolina Cuellar, Gerardo Ferrer, Sergey Gorlatov, Josep Nomdedéu, Emili Montserrat, Jorge Sierra, Kanti R. Rai, Nicholas Chiorazzi, and Carol Moreno

Disclosures: This work was supported in part by the Spanish Ministry of Science through grants from Red Temática de Investigación Cooperativa en Cáncer (RD12/0036/0071 to J.S) Instituto de Salud Carlos III (FIS PI11/01740 and FIS PI19/00753 to C.M), grants from Catalan Government AGAUR (2014 SGR 1281), Cellex Foundation Barcelona, Asociación Española contra el Cáncer (AECC), José Carreras Foundation and from the NIH, National Cancer Institute (RO1 CA0 81554 to NC). Sergey Gorlatov is an employee of MacroGenics, the manufacturer of the anti-Fc γ RIIb mAb used in this study, and receives compensation and stock options as part of his employment. All other authors declare no competing financial interests.

Contributions: RB and AM performed the laboratory work. RB, AM, GF, EM, NC and CM analyzed the results and wrote the paper. CC, SG, JN, JS and KR supplied essential data, samples or reagents. RB, AM, NC and CM designed the study. All authors have reviewed and approved the final version of the manuscript